Leerink Partnrs Predicts 10x Genomics Q1 Earnings

10x Genomics, Inc. (NASDAQ:TXG) – Stock analysts at Leerink Partnrs issued their Q1 2026 earnings per share estimates for 10x Genomics in a research report issued on Thursday, February 13th. Leerink Partnrs analyst P. Souda anticipates that the company will post earnings per share of ($0.35) for the quarter. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for 10x Genomics’ current full-year earnings is ($1.43) per share.

Several other research analysts have also recently commented on the company. JPMorgan Chase & Co. reduced their target price on 10x Genomics from $14.00 to $12.00 and set a “neutral” rating for the company in a research report on Thursday. Canaccord Genuity Group dropped their price objective on 10x Genomics from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday. Barclays dropped their price objective on 10x Genomics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Citigroup dropped their price objective on 10x Genomics from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday. Finally, Leerink Partners lowered 10x Genomics from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $25.00 to $12.00 in a research note on Thursday. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $20.57.

10x Genomics Price Performance

Shares of TXG stock opened at $12.31 on Friday. The stock has a market cap of $1.49 billion, a P/E ratio of -8.05 and a beta of 1.85. 10x Genomics has a one year low of $10.80 and a one year high of $51.22. The stock has a fifty day moving average price of $14.68 and a 200 day moving average price of $17.35.

10x Genomics (NASDAQ:TXG) last issued its earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%.

Institutional Trading of 10x Genomics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. RA Capital Management L.P. acquired a new stake in 10x Genomics in the fourth quarter worth about $47,092,000. Jane Street Group LLC increased its position in 10x Genomics by 48.4% in the fourth quarter. Jane Street Group LLC now owns 360,257 shares of the company’s stock worth $5,173,000 after purchasing an additional 117,449 shares during the period. Voleon Capital Management LP acquired a new stake in 10x Genomics in the fourth quarter worth about $205,000. PDT Partners LLC increased its position in 10x Genomics by 176.4% in the fourth quarter. PDT Partners LLC now owns 354,958 shares of the company’s stock worth $5,097,000 after purchasing an additional 226,513 shares during the period. Finally, Schonfeld Strategic Advisors LLC increased its position in 10x Genomics by 140.4% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 151,693 shares of the company’s stock worth $2,178,000 after purchasing an additional 88,583 shares during the period. 84.68% of the stock is currently owned by institutional investors and hedge funds.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.